Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.

ABSTRACT:

Importance

Anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopathy (DR) improvement and worsening. It is unknown whether these effects differ across anti-VEGF agents.

Objective

To compare changes in DR severity during aflibercept, bevacizumab, or ranibizumab treatment for DME.

Design, setting, and participants

Preplanned secondary analysis of data from a comparative effectiveness trial for center-involved DME was conducted in 650 participants receiving aflibercept, bevacizumab, or ranibizumab. Retinopathy improvement and worsening were determined during 2 years of treatment. Participants were randomized in 2012 through 2013, and the trial concluded on September 23, 2015.

Interventions

R

SUBMITTER: Bressler SB 

PROVIDER: S-EPMC5540030 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature